The lancet oncology
-
The lancet oncology · Jan 2025
ReviewThe changing global landscape of national cancer control plans.
Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden were first raised in 2005 World Health Assembly Resolution 58.22 and reinforced with Resolution 70.12 and the Global NCD action plan in 2017. One common thread for addressing cancer burden was the need to articulate cancer priorities within a comprehensive national cancer control plan (NCCP). ⋯ The global review included 16 new questions related to cancer equity, pandemic preparedness, global WHO initiatives, evidence-based recommendations, and other emerging trends. The findings can guide country-level decision makers on improvements to deliver person-centred cancer services to reduce the cancer burden.
-
The lancet oncology · Jan 2025
ReviewPulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
Lung neuroendocrine neoplasms are a group of diverse, heterogeneous tumours that range from well-differentiated, low-grade neuroendocrine tumours-such as typical and atypical carcinoids-to high-grade, poorly differentiated aggressive malignancies, such as large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC). While the incidence of SCLC has decreased, the worldwide incidence of other pulmonary neuroendocrine neoplasms has been increasing over the past decades. In addition to the standard histopathological classification of lung neuroendocrine neoplasms, the introduction of molecular and sequencing techniques has led to new advances in understanding the biology of these diseases and might influence future classifications and staging that can subsequently improve management guidelines in the adjuvant or metastatic settings. ⋯ This Review explores the epidemiology, diagnosis, and staging of lung neuroendocrine neoplasms to date. In addition, we focus on the evolving molecular landscape and biomarkers, ranging from tumour phenotypes to functional imaging studies and novel molecular biomarkers. We outline the various clinical outcomes, challenges, the treatment landscape, ongoing clinical trials, and future directions.
-
The lancet oncology · Jan 2025
Multicenter StudySafety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Effective treatment options are scarce for relapsed or refractory T-cell lymphoma. This study assesses the safety and activity of CTX130 (volamcabtagene durzigedleucel), a CD70-directed, allogeneic chimeric antigen receptor (CAR) immunotherapy manufactured from healthy donor T cells, in patients with relapsed or refractory T-cell lymphoma. ⋯ CRISPR Therapeutics.
-
The lancet oncology · Jan 2025
Multicenter StudyDeep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.
Accurate detection of driver gene mutations is crucial for treatment planning and predicting prognosis for patients with lung cancer. Conventional genomic testing requires high-quality tissue samples and is time-consuming and resource-consuming, and as a result, is not available for most patients, especially those in low-resource settings. We aimed to develop an annotation-free Deep learning-enabled artificial intelligence method to predict GEne Mutations (DeepGEM) from routinely acquired histological slides. ⋯ For the Chinese translation of the abstract see Supplementary Materials section.
-
The lancet oncology · Jan 2025
Observational StudyThe genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on the mutation burden in stem cells, patient survival, and toxicity. ⋯ Addenbrooke's Charitable Trust and Wellcome Trust.